The dental bone graft substitutes market is projected to reach US$1,400.46 million by 2034 from US$669.10 million in 2025. The market is estimated to register a CAGR of 8.6% during 2026-2034.

Major factors driving the market growth include the surging implant demand, aging global demographics, and advancements in surgical precision are propelling the adoption of dental bone graft substitutes. Further, emerging dental tourism hubs will likely boost the market during the forecast period. However, high procedure costs, safety & ethical concerns, regulatory hurdles are among the market deterrents.

The world's aging population is driving the dental bone graft substitutes market. As more people live longer, the need for restorative dental care and regenerative solutions is rising. According to the WHO, by 2050, the number of people aged 60 and over is expected to nearly double, from about 1 billion in 2020 to ~2.1 billion. The group aged 80 and above is set to triple. Older adults are more likely to experience oral health issues, including tooth loss, gum disease, and bone loss. This leads to a greater need for dental implants and bone grafting. Many seniors require stable bone support for implants to restore their chewing function, appearance, and quality of life. ~23% of people over 60 have lost all their teeth. Most individuals over 65 have some form of gum disease that reduces bone volume, making grafting crucial for successful implant placement.

Dental biomaterial manufacturers are responding to the needs of an aging population by developing new products that are safe, effective, and user-friendly for older patients. For example, Straumann introduced NeoCera, a synthetic ceramic graft that facilitates bone cell growth. Geistlich launched Bio-Oss Flex, a flexible graft that simplifies procedures for dentists. Zimmer Biomet's RegenerOss Plus includes growth factors to speed up healing in weak bone areas. BioHorizons' MinerOss AI utilizes artificial intelligence to enhance the effectiveness of the graft for various bone defect types.

The aging population is transforming the way dentists work. More dental professionals are utilizing fewer invasive techniques and digital tools, such as CBCT-guided graft placement, to serve older patients better. Many of these patients may have other underlying health issues. These changes indicate that as the number of older adults increases, demand for dental procedures rises. This encourages the development of new materials, the adoption of updated clinical practices, and greater involvement from manufacturers. As a result, the aging population is driving long-term growth in the dental bone graft substitutes market.

The comparative company analysis evaluates and categorizes the dental bone graft substitutes market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global dental bone graft substitutes market. The key market players are Dentsply Sirona Inc; Geistlich Pharma AG; ZimVie Inc; Straumann Holding AG; Medtronic Plc; Johnson & Johnson; BioHorizons Inc; LifeNet Health Inc; Henry Schein Inc; and Envista Holdings Corporation.

In terms of type, the dental bone graft substitutes market is bifurcated into allograft, autograft, xenograft, synthetic bone graft, and others. The xenograft segment held a larger market share in 2025, owing to acceptance due to their structural similarities to human bones that is leading the dental bone graft substitutes market.

Based on application, the dental bone graft substitutes market is categorized into socket preservation, ridge augmentation, periodontal defect regeneration, implant bone regeneration, and others. The socket preservation segment accounted for the largest share of the dental bone graft substitutes market in 2025. Socket preservation has become more common as more teeth are being extracted, people are more aware of bone loss after extraction, and there is a greater preference for less invasive procedures. This method helps maintain bone volume, improves the chances of successful implant placement later, and provides reliable results, which is why many clinicians use it.

Based on end user, the dental bone graft substitutes market is categorized into hospitals, clinics, and other end users. The hospitals segment held a larger share of the market in 2025. Hospitals had a bigger share because they have advanced surgical facilities, skilled oral surgeons, and more patients needing complex dental and facial procedures. Easier access to approved graft materials, insurance, and team-based care also leads to more use of these services in hospitals.

Companies operating in the dental bone graft substitutes market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses, enhance their geographic presence, and contribute to the overall market growth. Furthermore, acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few significant developments by key Dental Bone Graft Substitutes market players are listed below.

In July 2024, Dentsply Sirona updated its Symbios Allograft product line to emphasize enhanced sterility and versatility. The enhanced Symbios Allograft line offers both mineralized and demineralized regenerative solutions, tailored for various dental surgery and implant needs. These products are designed to promote bone formation, increase volume, and ensure stability for predictable, long-term outcomes. The updated portfolio features new granule allografts, putty products, and the acellular dermal matrix known as Symbios PerioDerm.

In February 2024, ZimVie Inc. announced the launch of the TSX Implant in Japan. The launch of TSX in Japan enables the company to directly compete with the leading players in the premium dental implant market.